Trials / Active Not Recruiting
Active Not RecruitingNCT06205628
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ADX-850 in Participants With Hypertension
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- ADARx Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX-850 | siRNA duplex oligonucleotide |
| DRUG | Placebo | Saline |
Timeline
- Start date
- 2024-03-21
- Primary completion
- 2026-06-30
- Completion
- 2026-09-30
- First posted
- 2024-01-16
- Last updated
- 2026-03-02
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT06205628. Inclusion in this directory is not an endorsement.